VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2023 | Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC

Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, presents expanded data from the microsatellite stable colorectal (MSS-CRC) expansion cohort of the Phase I study of botensilimab (NCT03860272), a multifunctional Fc-enhanced anti-CTLA-4, in combination with balstilimab, an anti-PD1 antibody, in metastatic heavily pre-treated MSS CRC. Efficacy was especially higher in patients without liver metastases, which form a significant minority of patients with MSS-CRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter